Literature DB >> 24518922

[Modern immunosuppression after solid organ transplantation].

J Beimler1, C Morath, M Zeier.   

Abstract

The one common factor in solid organ transplantation is the need for lifelong maintenance immunosuppression. Drug regimens after organ transplantation typically comprise a combination of different immunosuppressive drugs. In most cases a triple drug regimen with different mechanisms of action is used. The aim is to improve both patient and graft survival while minimizing potential side effects of immunosuppressive medication. The basis of most immunosuppressive regimens is calcineurin inhibitors in combination with mycophenolic acid. There are various stages of immunosuppression after solid organ transplantation involving induction therapy, initial and long-term maintenance therapy. In each phase an individual combination of immunosuppressants is set up depending on the risk profile of the individual patient to prevent transplant rejection and organ loss. Based on these considerations, concepts of calcineurin inhibitor or steroid reduction have been established in transplant medicine in recent years. The key role in terms of development of new immunosuppressive strategies is taken by kidney transplantation, the most common solid organ transplantation performed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24518922     DOI: 10.1007/s00108-013-3411-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

1.  Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

Authors:  H Tedesco Silva; D Cibrik; T Johnston; E Lackova; K Mange; C Panis; R Walker; Z Wang; G Zibari; Y S Kim
Journal:  Am J Transplant       Date:  2010-04-28       Impact factor: 8.086

2.  Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

Authors:  Herwig-Ulf Meier-Kriesche; Jesse D Schold; Titte R Srinivas; Bruce Kaplan
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

3.  Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency.

Authors:  A Zuckermann; Anne Keogh; M G Crespo-Leiro; D Mancini; F González Vilchez; L Almenar; S Brozena; H Eisen; S See Tai; S Kushwaha
Journal:  Am J Transplant       Date:  2012-07-09       Impact factor: 8.086

4.  Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Authors:  Lionel Rostaing; Pablo Massari; Valter Duro Garcia; Eduardo Mancilla-Urrea; Georgy Nainan; Maria del Carmen Rial; Steven Steinberg; Flavio Vincenti; Rebecca Shi; Greg Di Russo; Dolca Thomas; Josep Grinyó
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

5.  A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT.

Authors:  L Fischer; J Klempnauer; S Beckebaum; H J Metselaar; P Neuhaus; P Schemmer; U Settmacher; N Heyne; P-A Clavien; F Muehlbacher; I Morard; H Wolters; W Vogel; T Becker; M Sterneck; F Lehner; C Klein; G Kazemier; A Pascher; J Schmidt; F Rauchfuss; A Schnitzbauer; S Nadalin; M Hack; S Ladenburger; H J Schlitt
Journal:  Am J Transplant       Date:  2012-04-11       Impact factor: 8.086

Review 6.  Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.

Authors:  A Webster; R C Woodroffe; R S Taylor; J R Chapman; J C Craig
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

7.  Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.

Authors:  A S R Muthusamy; A C Vaidya; S Sinha; D Roy; D E Elker; P J Friend
Journal:  Am J Transplant       Date:  2008-10       Impact factor: 8.086

8.  Chronic kidney disease after nonrenal solid-organ transplantation.

Authors:  Roy D Bloom; Peter P Reese
Journal:  J Am Soc Nephrol       Date:  2007-12       Impact factor: 10.121

9.  Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

Authors:  Rita Alloway; Steven Steinberg; Kassem Khalil; Sita Gourishankar; Joshua Miller; Douglas Norman; Sundaram Hariharan; John Pirsch; Arthur Matas; Jeffrey Zaltzman; Kathleen Wisemandle; William Fitzsimmons; M Roy First
Journal:  Transplantation       Date:  2007-06-27       Impact factor: 4.939

Review 10.  Cyclosporin versus tacrolimus for liver transplanted patients.

Authors:  E M Haddad; V C McAlister; E Renouf; R Malthaner; M S Kjaer; L L Gluud
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18
View more
  4 in total

1.  [Skin cancer screening and treatment costs : Utilisation of the skin cancer screening and skin cancer treatment costs in organ transplant recipients].

Authors:  D Jäckel; N I Schlothauer; H Zeeb; G Wagner; M M Sachse
Journal:  Hautarzt       Date:  2018-07       Impact factor: 0.751

2.  Drug repurposing: Ibrutinib exhibits immunosuppressive potential in organ transplantation.

Authors:  Qing Zhang; Jicheng Chen; Hanchao Gao; Song Zhang; Chengjiang Zhao; Cuibing Zhou; Chengjun Wang; Yang Li; Zhiming Cai; Lisha Mou
Journal:  Int J Med Sci       Date:  2018-07-13       Impact factor: 3.738

3.  Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study.

Authors:  Majda Sahman; Snezana Mugosa; Nemanja Rancic
Journal:  Front Public Health       Date:  2021-03-31

4.  SARS-CoV-2 infection in liver transplant recipients: A complex relationship.

Authors:  Ricardo Wesley Alberca; Gil Benard; Gabriela Gama Freire Alberca; Maria Notomi Sato
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.